Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02073487 (TEAL) (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel (TEAL) (NCT02073487)

Trial Description
The purpose of this study is to evaluate the Pathological Complete Response (pCR) of the breast when ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) plus lapatinib (Tykerb®; Novartis Pharmacueticals Co. plus paclitaxel (Abraxane®; Celgene Corp.). is combined in newly diagnosed HER2 positive breast cancer.

This is a randomized, open label Phase II neo-adjuvant study comparing the efficacy of neoadjuvant Trastuzumab Emtansine (TDM1) plus lapatinib follow by Abraxane, versus trastuzumab (Herceptin®;Genentech, Inc.) plus Lapatinib follow by pacitaxel.

This trial is sponsored by The Methodist Hospital System. [1]

 

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar